전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved110 programs
CGTLimited DatastaleThe Children's Hospital of Zhej…Phase 1

UCAR T-cell (UCAR T-cell)

Autoimmune Diseases; Systemic Lupus Erthematosus (SLE) · Autoimmune Diseases

#AutoimmuneDiseases#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleDavid WaldPhase 1

UF-KURE-BCMA CAR T-cells (UF-KURE-BCMA CAR T-cells)

Multiple Myeloma; Multiple Myeloma in Relapse · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 1

Universal CD7-specific CAR gene-engineered T cells (Universal CD7-specific CAR gene-engineered T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Acute Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

CNK-UT (Universal Chimeric Natural Killer Receptor Modified T-cells, Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleShanghai First Song Biotechnolo…Phase 1

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells (anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells)

Relapsed/refractory Lymphoma; Relapsed/Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai General Hospital, Shan…Phase 1

anti-CD7 CAR-T cells (anti-CD7 CAR-T cells)

T Lymphoblastic Leukemia/Lymphoma; T-cell Acute Lymphoblastic Leukemia · T Lymphoblastic Leukemia/Lymphoma

#TLymphoblasticLeukemiaLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

iC9.GD2.CAR.IL-15 T-cells (iC9.GD2.CAR.IL-15 T-cells)

Neuroblastoma; Osteosarcoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBeiGenePreclinical

tislelizumab, azacytidine, lenalidomide (tislelizumab, azacytidine, lenalidomide)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Preclinical#monoclonal-antibody#NaturalKiller+3
Trials 1Status Active
AntibodyLimited DatastaleBeiGenePreclinical

tislelizumab, etoposide, pegaspargase (tislelizumab, etoposide, pegaspargase)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Preclinical#monoclonal-antibody#NaturalKiller+3
Trials 1Status Active
CGTLimited DatastaleMingfeng ZhaoPhase 1

universal CLL1 CAR-T cells (universal CLL1 CAR-T cells)

Acute Myeloid Leukemia; Chimeric Antigen Receptor T-cell · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

6 / 6 pages

← PreviousNext →